Brief: Gilead And Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced The Risk Of Death In Third-Line Metastatic Colorectal Cancer

Arcus Biosciences

02/06/2024 13:05

June 2 (Reuters) - Gilead Sciences Inc  GILD.O :
    * GILEAD AND ARCUS ANNOUNCE ETRUMADENANT PLUS ZIMBERELIMAB
REGIMEN
SIGNIFICANTLY REDUCED THE RISK OF DEATH IN THIRD-LINE METASTATIC
COLORECTAL CANCER

Source text for Eikon:  ID:nBw4Xy5tta 
Further company coverage:  GILD.O 

 ((Reuters.Briefs@thomsonreuters.com;))